Join Growin Stock Community!

Idexx laboratories, inc.IDXX.US Overview

US StockHealthcare
(No presentation for IDXX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IDXX AI Insights

IDXX Overall Performance

IDXX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IDXX Recent Performance

-3.91%

Idexx laboratories, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IDXX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IDXX Key Information

IDXX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IDXX Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Price of IDXX

IDXX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IDXX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
13.27
PE Ratio (TTM)
50.25
Forward PE
47.03
PS Ratio (TTM)
12.21
PB Ratio
32.86
Price-to-FCF
48.72
METRIC
VALUE
vs. INDUSTRY
Gross Margin
61.80%
Net Margin
24.62%
Revenue Growth (YoY)
10.42%
Profit Growth (YoY)
11.80%
3-Year Revenue Growth
9.59%
3-Year Profit Growth
10.72%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
13.27
PE Ratio (TTM)
50.25
Forward PE
47.03
PS Ratio (TTM)
12.21
PB Ratio
32.86
Price-to-FCF
48.72
Gross Margin
61.80%
Net Margin
24.62%
Revenue Growth (YoY)
10.42%
Profit Growth (YoY)
11.80%
3-Year Revenue Growth
9.59%
3-Year Profit Growth
10.72%
  • When is IDXX's latest earnings report released?

    The most recent financial report for Idexx laboratories, inc. (IDXX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IDXX's short-term business performance and financial health. For the latest updates on IDXX's earnings releases, visit this page regularly.

  • Where does IDXX fall in the P/E River chart?

    According to historical valuation range analysis, Idexx laboratories, inc. (IDXX)'s current price-to-earnings (P/E) ratio is 47.77, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of IDXX?

    According to the latest financial report, Idexx laboratories, inc. (IDXX) reported an Operating Profit of 315.61M with an Operating Margin of 28.94% this period, representing a growth of 20.6% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IDXX's revenue growth?

    In the latest financial report, Idexx laboratories, inc. (IDXX) announced revenue of 1.09B, with a Year-Over-Year growth rate of 14.28%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IDXX have?

    As of the end of the reporting period, Idexx laboratories, inc. (IDXX) had total debt of 948.99M, with a debt ratio of 0.28. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IDXX have?

    At the end of the period, Idexx laboratories, inc. (IDXX) held Total Cash and Cash Equivalents of 180.07M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IDXX go with three margins increasing?

    In the latest report, Idexx laboratories, inc. (IDXX) achieved the “three margins increasing” benchmark, with a gross margin of 60.3%%, operating margin of 28.94%%, and net margin of 22.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IDXX's profit trajectory and future growth potential.

  • Is IDXX's EPS continuing to grow?

    According to the past four quarterly reports, Idexx laboratories, inc. (IDXX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 3.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IDXX?

    Idexx laboratories, inc. (IDXX)'s Free Cash Flow (FCF) for the period is 312.78M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 40.4% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IDXX?

    The latest valuation data shows Idexx laboratories, inc. (IDXX) has a Price-To-Earnings (PE) ratio of 47.77 and a Price/Earnings-To-Growth (PEG) ratio of -5.67. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.